Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (360)	12/26/2008 7:45:56 AM
From: C.Carlos	Read Replies (1) \| Respond to of 411

I love this CYA part: >>Several risks could drive the stock to materially outperform our target price. As a case in point, if positive safety data from MERLIN drives increased market penetration in 1st-line chronic angina, Ranexa sales might be higher than we predict. In addition, if Lexiscan exceeds our estimates, there could be an upside to the stock.<< He is basically saying: "I will be wrong if I am not right." I find his rating and reasoning shallow, at best, and suspect, at worse.